Evidence map›Paper›PMID 31211328›Full record

ArticleJAMA2019

Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic System to the Test.

David Wolk, Stephen Salloway, Brad Dickerson

Abstract readEditorialComment
In one paragraph

Article in JAMA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Radiomics-enhancedEuropean radiology experimental · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

David WolkDepartment of Neurology, University of Pennsylvania, Philadelphia.
Stephen SallowayDepartments of Psychiatry and Neurology, Alpert Medical School, Brown University, Providence, Rhode Island.
Brad DickersonFrontotemporal Disorders Unit & Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.

Funding

UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
Modulators of Medial Temporal Lobe Subregion Structure and Function in Normal and Pathological AgingR01AG055005 · NIA · UNIVERSITY OF PENNSYLVANIA · PI WOLK, DAVID A · 2017 to 2021
$3.3M
NIA NIH HHS P30 AG010124NIA NIH HHS R01 AG055005
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseaseDementiaAmyloidBiomarkersHumansMemory DisordersAmyloidBiomarkers

Identifiers

PMID31211328
PMCPMC7797952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.